BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
See today's BioWorld
Home
» Biogen brings FA drug into the fold with $7.3B Reata acquisition
To read the full article
sign up for free
or
sign in
.
Biogen brings FA drug into the fold with $7.3B Reata acquisition
July 28, 2023
By
Lee Landenberger
In the second-biggest M&A deal so far in 2023, Biogen Inc. plans to acquire Reata Pharmaceuticals Inc. for an enterprise value of about $7.3 billion.
BioWorld
Deals and M&A
Acquisition